Dmitry Morosov

Article Abstract:

Dmitry Morosov, a biotech entrepreneur from Moscow, wants to capitalize transforming untapped Russian scientific excellence into innovative biotech products. Morosov founded Biocad, a biotech company based on the outskirts of Moscow, who's business strategy aims at undercutting imported medicines and manufacturing generic versions of biologics on his home turf, marketing them at lower prices first in Russia and later in international markets.

Executive changes & profiles, Russia, Innovations, Officials and employees, Morosov, Dmitry

---

New EU antitrust law burdens licensing

Article Abstract:

The European Commission (EC, Brussels) has implemented New Technology Transfer Block Exemption Regulations (TTBER) to define rules for companies to comply with licensing agreements so as not to hinder competition. Most biotech companies consider the guidelines complicated and disagree with some of the criteria necessary for exemption.

Alliances, partnerships, Licensing/Sales Agreements, Technology application, Licensing agreements, European Union. European Commission, Company licensing agreement, Technology Transfer Institute

---

Julian Thurston

Article Abstract:

Julian Thurston, a commercial lawyer in the United Kingdom, states that early-stage biotech venture development is fettered by the shortsighted investment strategies in Europe. He gives his views on the future of the European biotech sector and expects the biotech sector to rethink its strategies for its success.

United Kingdom, Legal issues & crime, Government regulation (cont), Government regulation, Legal services, Attorneys, Offices of Lawyers, Legal/Government Regulation, Methods, Laws, regulations and rules, Lawyers, Interview, Strategic planning (Business), Thurston, Julian

Similar abstracts:

• Abstracts: Rating focus. Asian hedge funds. SEC likely to change rules for securities offerings to attract foreign issuers
• Abstracts: Room for improvement. Caught in the act. Our voice
• Abstracts: Politics torpedo biotech as EU priority. Taiwan: biotech vision. Germany biotech gets second chance
• Abstracts: Disability insurance revisited. American Jobs Creation Act. The IRS and your salary: old rules, new games
• Abstracts: Daptomycin. Rosuvastatin calcium. Gefitinib

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.